TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: KAN-DO: A Family-based Intervention to Prevent Childhood Obesity
Brief Summary: The purpose of this study is to evaluate the efficacy of an intervention (KAN-DO: Kids \& Adults Now - Defeat Obesity) encouraging postpartum mothers and their preschool-aged children to work together to promote healthy eating, increase physical activity, and reduce sedentary behaviors. Via instruction in parenting skills and behavior change strategies, the goal is relative weight maintenance in children of healthy weight, and relative weight reduction in overweight children. The intervention will focus on a child (2-5 years of age) and his or her overweight or obese mother, who has just delivered a second or subsequent baby.


Options:
A: Change in vegetable intake (Measured at child age of 4-6 months (prior to intervention), 18 months (directly after intervention) and at child age of 24 and 36 months (6 and 18 months follow-up)); Change in vegetable liking (Measured at child age of 4-6 months (prior to intervention), 18 months (directly after intervention) and at child age of 24 and 36 months (6 and 18 months follow-up)); Child self-regulation of energy intake (Measured at child age of 18 months); Change in child self-regulation of energy intake (Measured at child age of 4-6 months (prior to intervention), 18 months (directly after intervention) and at child age of 24 and 36 months (6 and 18 months follow-up))
B: Change in Child Body Mass Index (BMI Z-score) (Change from Baseline at 12 and 21 months)
C: Change in child's fruit and vegetable intake as measured by short dietary screener (Baseline to 4 months, 12 month follow-up, 16-month follow-up, 24-month follow-up, and 28-month follow-up); Change in child's fruit and vegetable intake as measured by 24-hour dietary recall (Baseline to 4 months, 16-month follow-up, and 28-month follow-up); Change in child's intake of sugar-sweetened beverages and processed snacks as measured by short dietary questionnaire (Baseline to 4 months, 12-month follow-up, 16-month follow-up, 24-month follow-up, and 28-month follow-up); Change in child's intake of sugar-sweetened beverages and processed snacks as measured by 24-hour dietary recall (Baseline to 4 months, 16-month follow-up, and 28-month follow-up); Change in child's caloric intake as a percent of estimated energy requirements (Baseline to 4 months, 16-month follow-up, and 28-month follow-up); Change in child's dermal carotenoid levels (Baseline to 4 months, 16-month follow-up, and 28-month follow-up); Change in child's diet quality (Baseline to 4 months, 16-month follow-up, and 28-month follow-up)
D: BMI z-score (via measured weight and height) of preschooler (~2 years post baseline)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: KAN-DO: A Family-based Intervention to Prevent Childhood Obesity
Brief Summary: The purpose of this study is to evaluate the efficacy of an intervention (KAN-DO: Kids \& Adults Now - Defeat Obesity) encouraging postpartum mothers and their preschool-aged children to work together to promote healthy eating, increase physical activity, and reduce sedentary behaviors. Via instruction in parenting skills and behavior change strategies, the goal is relative weight maintenance in children of healthy weight, and relative weight reduction in overweight children. The intervention will focus on a child (2-5 years of age) and his or her overweight or obese mother, who has just delivered a second or subsequent baby.


Options:
A: Maintenance of a Child's Body Mass Index as a result of the intervention (up to two years)
B: BMI z-score (via measured weight and height) of preschooler (~2 years post baseline)
C: Body mass index (2005, 2006, 2007, 2008); nutrition behavior (2005, 2006, 2007, 2008); physical activity (2005, 2006, 2007, 2008)
D: % Body Fat (Boys) (Baseline and 3 years); BMI Z-score (Boys) (Baseline and three years); % Body Fat (Girls) (Baseline and 3 years); BMI Z-score (Girls) (Baseline and three years)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: KAN-DO: A Family-based Intervention to Prevent Childhood Obesity
Brief Summary: The purpose of this study is to evaluate the efficacy of an intervention (KAN-DO: Kids \& Adults Now - Defeat Obesity) encouraging postpartum mothers and their preschool-aged children to work together to promote healthy eating, increase physical activity, and reduce sedentary behaviors. Via instruction in parenting skills and behavior change strategies, the goal is relative weight maintenance in children of healthy weight, and relative weight reduction in overweight children. The intervention will focus on a child (2-5 years of age) and his or her overweight or obese mother, who has just delivered a second or subsequent baby.


Options:
A: BMI z-score (via measured weight and height) of preschooler (~2 years post baseline)
B: Change in fruit, vegetable, whole grain in the lunch sack from baseline to 6 weeks, 22 weeks, and 28 weeks (Baseline, 6 weeks, 22 weeks, 28 weeks)
C: BMI percentile at 3 years (3 years)
D: Intake of vegetables and fruit (One month)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: KAN-DO: A Family-based Intervention to Prevent Childhood Obesity
Brief Summary: The purpose of this study is to evaluate the efficacy of an intervention (KAN-DO: Kids \& Adults Now - Defeat Obesity) encouraging postpartum mothers and their preschool-aged children to work together to promote healthy eating, increase physical activity, and reduce sedentary behaviors. Via instruction in parenting skills and behavior change strategies, the goal is relative weight maintenance in children of healthy weight, and relative weight reduction in overweight children. The intervention will focus on a child (2-5 years of age) and his or her overweight or obese mother, who has just delivered a second or subsequent baby.


Options:
A: BMI z-score (via measured weight and height) of preschooler (~2 years post baseline)
B: BMI percentile at 3 years (3 years)
C: Absolute change in mean accelerometry counts over 6 days (baseline, end of intervention, six months after end of intervention)
D: Food intake (1 month)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: KAN-DO: A Family-based Intervention to Prevent Childhood Obesity
Brief Summary: The purpose of this study is to evaluate the efficacy of an intervention (KAN-DO: Kids \& Adults Now - Defeat Obesity) encouraging postpartum mothers and their preschool-aged children to work together to promote healthy eating, increase physical activity, and reduce sedentary behaviors. Via instruction in parenting skills and behavior change strategies, the goal is relative weight maintenance in children of healthy weight, and relative weight reduction in overweight children. The intervention will focus on a child (2-5 years of age) and his or her overweight or obese mother, who has just delivered a second or subsequent baby.


Options:
A: Healthy food purchasing and related-psychosocial factors (Up to 8 months)
B: BMI z-score (via measured weight and height) of preschooler (~2 years post baseline)
C: Body mass index (BMI) >= 85th percentile, adjusted for gender and age (baseline, end of 7th grade, end of study); Fasting glucose (mg/dL) (baseline, end of study); Fasting insulin (mU/mL) (baseline, end of study)
D: Change in body weight from baseline (4 weeks)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: KAN-DO: A Family-based Intervention to Prevent Childhood Obesity
Brief Summary: The purpose of this study is to evaluate the efficacy of an intervention (KAN-DO: Kids \& Adults Now - Defeat Obesity) encouraging postpartum mothers and their preschool-aged children to work together to promote healthy eating, increase physical activity, and reduce sedentary behaviors. Via instruction in parenting skills and behavior change strategies, the goal is relative weight maintenance in children of healthy weight, and relative weight reduction in overweight children. The intervention will focus on a child (2-5 years of age) and his or her overweight or obese mother, who has just delivered a second or subsequent baby.


Options:
A: Develop/evaluate effectiveness of a community-based intervention targets children of the Pacific Region who are overweight in order to slow and prevent further weight gain (for children to "grow into their weight") (Feb 2008 - Feb 2012)
B: BMI z-score (via measured weight and height) of preschooler (~2 years post baseline)
C: Body Mass Index Z-score (0, 6, 12, and 18 months)
D: Improved dietary quality (Baseline- 24 months); Increased physical activity (Baseline- 24 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: KAN-DO: A Family-based Intervention to Prevent Childhood Obesity
Brief Summary: The purpose of this study is to evaluate the efficacy of an intervention (KAN-DO: Kids \& Adults Now - Defeat Obesity) encouraging postpartum mothers and their preschool-aged children to work together to promote healthy eating, increase physical activity, and reduce sedentary behaviors. Via instruction in parenting skills and behavior change strategies, the goal is relative weight maintenance in children of healthy weight, and relative weight reduction in overweight children. The intervention will focus on a child (2-5 years of age) and his or her overweight or obese mother, who has just delivered a second or subsequent baby.


Options:
A: BMI z-score (via measured weight and height) of preschooler (~2 years post baseline)
B: Absolute change in mean accelerometry counts over 6 days (baseline, end of intervention, six months after end of intervention)
C: Intake of vegetables and fruit (One month)
D: Change in EPAO-SR Scores from Baseline to Post-intervention (Measures collected at baseline (2-4 weeks prior to the intervention) and post-intervention (1-3 weeks following the intervention))

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Interest of Treatment of Polytraumatisms With Corticoids (Hydrocortisone) for Patient With Relative Adrenocortical Insufficiency
Brief Summary: Interest of treatment of polytraumatisms with corticoids (hydrocortisone) for patient with relative adrenocortical insufficiency on frequency of nosocomial infection, and hemodynamic complications and organs injuries.


Options:
A: mortality
B: Incidence of nosocomial pneumopathy: radiological, clinical and bacteriological criteria (28 days)
C: Length of stay in ICU and length of stay in the hospital. (2 years)
D: Time to clinical stability (30 days)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Catheters Dysfunction Rate After Instillation of Ethanol 60% Lock Solution in Tunneled Silicone Catheter of Chronic Hemodialysis Patients
Brief Summary: The primary objective of the study is to examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis.

The catheters dysfunction rate is the primary outcome. The dysfunction is defined as partial or complete occlusion or infection associated with dialysis catheter.

As a secondary outcome, the dialysis quality is also examined (urea reduction rate, total ultrafiltration)


Options:
A: Success Rate (90 days)
B: Number of Participants With Microbiological Response at Test-of-Cure (TOC) Visit (Short term follow-up (STFU) visit for TOC (2 to 3 weeks after the last dose of study medication))
C: Treatment Success (28 days)
D: The catheters dysfunction rate (as partial or complete occlusion or infection associated with dialysis catheter)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients (a Randomised, Double-blind, Double-dummy, Parallel Group, One-year Study).
Brief Summary: This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD. There will be a two-week run-in period followed by a 52-week randomised treatment phase. Patients who withdraw prematurely from trial medication will be encouraged to remain in the trial and participate in follow-up telephone contacts until their predicted normal exit date from the trial (i.e. 52 weeks after taking the first dose of randomised treatment). The phone calls will be made at all scheduled visits.

The primary objective of this study is to compare the effect of tiotropium (18 mcg) inhalation capsule via HandiHaler with that of salmeterol (50 mcg) via MDI on COPD exacerbations.

The primary endpoint is time to first COPD exacerbation during the 52 week randomised treatment period. A COPD exacerbation will be defined as a complex of respiratory events / symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnoea or chest tightness with at least one symptom lasting at least three days requiring treatment with antibiotics and/or systemic steroids and/or hospitalisation.

The onset of an exacerbation is defined as the onset of the first new or increased reported symptom. The end of the exacerbation should be recorded as defined by the investigator.

Only COPD exacerbations with onset during randomised treatment will be included in the analysis.


Options:
A: First Occurrence of (Moderate or Severe) COPD Exacerbation (52 weeks)
B: Trough Forced Expiratory Volume in 1 Second (FEV1) at End of Treatment (Week 12) (End of treatment (Week 12))
C: FEV1 AUC0-3h Response at 12 Weeks; Defined as Change From Baseline to Week 12 (baseline and 12 weeks); Trough FEV1 Response at 12 Weeks; Defined as Change From Baseline to Week 12 (baseline and 12 weeks)
D: Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of Treatment (Week 12 + 1 Day, Day 85) (End of treatment (Week 12 + 1 day, Day 85))

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients (a Randomised, Double-blind, Double-dummy, Parallel Group, One-year Study).
Brief Summary: This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD. There will be a two-week run-in period followed by a 52-week randomised treatment phase. Patients who withdraw prematurely from trial medication will be encouraged to remain in the trial and participate in follow-up telephone contacts until their predicted normal exit date from the trial (i.e. 52 weeks after taking the first dose of randomised treatment). The phone calls will be made at all scheduled visits.

The primary objective of this study is to compare the effect of tiotropium (18 mcg) inhalation capsule via HandiHaler with that of salmeterol (50 mcg) via MDI on COPD exacerbations.

The primary endpoint is time to first COPD exacerbation during the 52 week randomised treatment period. A COPD exacerbation will be defined as a complex of respiratory events / symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnoea or chest tightness with at least one symptom lasting at least three days requiring treatment with antibiotics and/or systemic steroids and/or hospitalisation.

The onset of an exacerbation is defined as the onset of the first new or increased reported symptom. The end of the exacerbation should be recorded as defined by the investigator.

Only COPD exacerbations with onset during randomised treatment will be included in the analysis.


Options:
A: Trough FEV1 (L) at 28 Weeks on Treatment (28 weeks); Trough FEV1 (L) at 12 Weeks on Treatment (12 weeks)
B: First Occurrence of (Moderate or Severe) COPD Exacerbation (52 weeks)
C: Pre-dose Forced Expiratory Volume in One Second (FEV1) (Before randomization, 0, 4, 8 and 12 weeks after randomization)
D: Change from baseline in trough FEV1 (Forced expiratory volume in one second) (after 12 weeks); Change from baseline in FEV1 2 hours post inhalation (after 12 weeks)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients (a Randomised, Double-blind, Double-dummy, Parallel Group, One-year Study).
Brief Summary: This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD. There will be a two-week run-in period followed by a 52-week randomised treatment phase. Patients who withdraw prematurely from trial medication will be encouraged to remain in the trial and participate in follow-up telephone contacts until their predicted normal exit date from the trial (i.e. 52 weeks after taking the first dose of randomised treatment). The phone calls will be made at all scheduled visits.

The primary objective of this study is to compare the effect of tiotropium (18 mcg) inhalation capsule via HandiHaler with that of salmeterol (50 mcg) via MDI on COPD exacerbations.

The primary endpoint is time to first COPD exacerbation during the 52 week randomised treatment period. A COPD exacerbation will be defined as a complex of respiratory events / symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnoea or chest tightness with at least one symptom lasting at least three days requiring treatment with antibiotics and/or systemic steroids and/or hospitalisation.

The onset of an exacerbation is defined as the onset of the first new or increased reported symptom. The end of the exacerbation should be recorded as defined by the investigator.

Only COPD exacerbations with onset during randomised treatment will be included in the analysis.


Options:
A: First Occurrence of (Moderate or Severe) COPD Exacerbation (52 weeks)
B: Rate of healthcare utilisation based exacerbations of COPD
C: Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 5 Minutes to 11 Hours 45 Minutes Post-dose at the End of the Study (Week 12, Day 84) (From 5 minutes to 11 hours 45 minutes post-dose at the end of the study (Week 12, Day 84))
D: Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years (From day 30 to 4 years); Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years (From day 30 to 4 years)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients (a Randomised, Double-blind, Double-dummy, Parallel Group, One-year Study).
Brief Summary: This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD. There will be a two-week run-in period followed by a 52-week randomised treatment phase. Patients who withdraw prematurely from trial medication will be encouraged to remain in the trial and participate in follow-up telephone contacts until their predicted normal exit date from the trial (i.e. 52 weeks after taking the first dose of randomised treatment). The phone calls will be made at all scheduled visits.

The primary objective of this study is to compare the effect of tiotropium (18 mcg) inhalation capsule via HandiHaler with that of salmeterol (50 mcg) via MDI on COPD exacerbations.

The primary endpoint is time to first COPD exacerbation during the 52 week randomised treatment period. A COPD exacerbation will be defined as a complex of respiratory events / symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnoea or chest tightness with at least one symptom lasting at least three days requiring treatment with antibiotics and/or systemic steroids and/or hospitalisation.

The onset of an exacerbation is defined as the onset of the first new or increased reported symptom. The end of the exacerbation should be recorded as defined by the investigator.

Only COPD exacerbations with onset during randomised treatment will be included in the analysis.


Options:
A: Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 + 1 Day, Day 85 (Week 12 + 1 day, Day 85)
B: Time-normalized Area Under the Change From Study Baseline Curve for Forced Expiratory Volume in One Second (FEV1) Over 24 Hours (nAUC0-24B) (24 hours following two weeks of dosing.)
C: First Occurrence of (Moderate or Severe) COPD Exacerbation (52 weeks)
D: 24-hour Post-dose Trough Forced Expiratory Volume in 1 Second (FEV1) After 14 Days of Treatment (23 hours 10 minutes and 23 hours 45 minutes post-dose on Day 15 of each treatment period)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
Brief Summary: 224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78) or ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic.


Options:
A: Reduction in clinical signs and symptoms of infection (Study day 10)
B: Number of Participants With a Clinical Cure at Visit 3 (Day 7) (Day 7 of treatment)
C: Reduction in clinical signs and symptoms of the infection (Study day 10)
D: Number of healing patients (12 weeks)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
Brief Summary: 224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78) or ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic.


Options:
A: Number of Participants With a Clinical Cure at Visit 3 (Day 7) (Day 7 of treatment)
B: Reduction in clinical signs and symptoms of infection (Study day 10)
C: Number of healing patients (12 weeks)
D: Reduction in clinical signs and symptoms of the infection (Study day 10)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Very Early Surfactant Without Mandatory Ventilation In Premature Infants Treated With Early Continuous Positive Airway Pressure-A Randomized Controlled Trial
Brief Summary: The present study will test the use of very early nasal continuous airway pressure(NCPAP)with and without surfactant in premature infants with clinical evidence or respiratory distress syndrome. We hypothesize that premature infants exposed to very early NCPAP and surfactant will require less mechanical ventilation compared to those premature infants exposed to NCPAP alone.


Options:
A: Survival Without Bronchopulmonary Dysplasia (BPD) (36 weeks); Survival Without Severe Retinopathy of Prematurity (ROP) (Threshold Disease or the Need for Surgery) (55 weeks)
B: Need for mechanical ventilation (Death or discharge from the NICU)
C: Need for mechanical ventilation
D: Need for MV (Within the first 5 days of life)

Answer: B